Brand name · Satralizumab
Enspryng: adverse event reports filed with FDA
1,359 reports list it as a suspect or interacting product, 2020–2026.
- 1,359
- reports as suspect product
- 0% of all reports · about 233 a year
- 296
- reports, 12 months to June 2026
- 362 in the 12 months before
- 74%
- marked serious by the reporter
- 57.4% across all reports
- 5.7%
- record death among outcomes, as reported
- 78 reports · not verified by FDA
Between September 2020 and June 2026, 1,359 adverse event reports received by FDA list the brand name Enspryng (satralizumab) as a suspect or interacting product. Reports that mention it only as a concomitant medication (21) are left out of every figure here.
In the 12 months to June 2026, 296 reports listed it, down 18% from 362 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 233 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded neuromyelitis optica spectrum disorder (15.7%), urinary tract infection (7.6%) and off label use (7.5%). A report can list several reactions, so shares add to more than 100%; 302 different terms appear across these reports. Neuromyelitis optica spectrum disorder is recorded in 15.7% of these reports, against 0% of all reports in the database.
74% of the reports are marked serious by the reporter; 5.7% record death among the outcomes and 36.9% record hospitalisation, as reported. 53% of the reports came from physicians, and the largest patient age group is 45 to 64 (30.8%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Enspryng reports recording the termall reports in the database
- Neuromyelitis optica spectrum disorder15.7%213
- Urinary tract infectionbladder or urinary infection7.6%103
- Off label useused for a purpose or in a way not on the label7.5%102
- Pneumonialung infection6.1%83
- No adverse eventno adverse event was reported4.5%61
- Covid-19COVID-19 infection4%54
- Fatiguetiredness3.2%43
- Headachehead pain2.9%40
- Hypoaesthesianumbness2.6%36
- Painpain, site not specified2.6%36
- Arthralgiajoint pain2.6%35
- Infectionan infection, type not specified2.2%30
- Product dose omission issuea dose was missed2.1%28
- Pyrexiafever2.1%28
- Sepsisa severe body-wide response to infection2.1%28
- Nauseafeeling sick2%27
- Falla fall1.8%25
- Astheniaweakness or lack of energy1.8%24
- Malaisegeneral feeling of being unwell1.8%24
- Nasopharyngitisa cold1.8%24
- Gait disturbancedifficulty walking1.6%22
- Influenzaflu1.6%22
- Cellulitisa skin infection1.5%21
- Deaththe patient died; cause not stated by this term1.5%21
- Muscular weaknessmuscle weakness1.5%21
- Blindnessloss of sight1.4%19
- Herpes zostershingles1.4%19
- Rashskin rash1.4%19
- Septic shockshock arising from infection1.3%18
Top 30 of 302 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 39.8% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Neuromyelitis optica spectrum disorder | 1,193 | 87.8% |
| Myelin oligodendrocyte glycoprotein antibody-associated disease | 11 | 0.8% |
| Demyelination | 5 | 0.4% |
| Autoimmune disorder | 2 | 0.1% |
| Multiple sclerosis | 2 | 0.1% |
| Myelitis | 2 | 0.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,359 reports.
In context
| Measure | Enspryng | All reports |
|---|---|---|
| Reports as suspect product | 1,359 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 296 | 1,332,454 |
| Marked serious | 74% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 57 | 91 |
| Hospitalisation recorded, per 1,000 reports | 369 | 213 |
| Consumer-filed share | 37.2% | 45.8% |
| Top term, share of reports | Neuromyelitis optica spectrum disorder 15.7% | 0% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Enspryng reports
How many adverse event reports has FDA received for Enspryng?
1,359 reports list Enspryng as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 296 of them arrived in the latest 12 months. Another 21 list it only as a concomitant medication.
What reactions are recorded in Enspryng reports?
neuromyelitis optica spectrum disorder (15.7%), urinary tract infection (7.6%), off label use (7.5%), pneumonia (6.1%) and no adverse event (4.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Enspryng was responsible.
How serious are the reports?
74% are marked serious by the reporter. Among the outcomes recorded, 5.7% of reports include death and 36.9% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (53%), consumer or non-health professional (37.2%) and other health professional (5.5%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Enspryng rising?
296 reports in the 12 months to June 2026, down 18% from 362 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Enspryng was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Enspryng?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Enspryng as a suspect or interacting product; reports listing it only as a concomitant medication (21) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.